France’s Pasteur Institute said on Monday it was ending development of a Covid-19 vaccine with US pharmaceutical company Merck after clinical trial results proved disappointing.
The partners announced a tie-up last May to develop a jab based on an existing measles vaccine, which was put into Phase 1 clinical trials in August.
“In these first human trials, the prospective vaccine was well tolerated but produced immune responses that were inferior to those observed in people who had recovered naturally and to those observed in the authorised vaccines,” a statement from Pasteur Institute said.
